Executive Summary
Revvity Inc delivered a solid QQ2 2025 performance with meaningful top-line growth anchored by its Diagnostics and Discovery platforms. Revenue reached $720.3 million, up 5.3% year over year and 8.3% quarter over quarter, while gross margin held strong at 54.5%, yielding gross profit of $392.6 million. EBITDA stood at $194.4 million and operating income was $90.8 million, resulting in an operating margin of 12.6% and a net margin of 7.7% on the quarter. Net income was $55.2 million, or $0.47 per share, reflecting ongoing operating efficiency alongside continued investment spend.
Key Performance Indicators
QoQ: 33.27% | YoY:-41.23%
QoQ: 36.27% | YoY:-38.57%
Key Insights
Revenue: $720.284m (+5.3% YoY, +8.35% QoQ); Gross Margin: 54.5% (Gross Profit $392.556m); Operating Margin: 12.6%; EBITDA: $194.365m; Net Income: $55.222m; EPS: $0.47; R&D: $53.27m; SG&A: $250.221m; Operating Expenses: $301.796m; Cash from Ops: $134.318m; Free Cash Flow: $115.45m; Cash at End of Period: $992.99m; Net Debt: $2.383b; Total Assets: $12.363b; Current Ratio: 3.33; Debt/Capitalization: 0.309; Debt/EBITDA: ~12.3x....
Financial Highlights
Revenue: $720.284m (+5.3% YoY, +8.35% QoQ); Gross Margin: 54.5% (Gross Profit $392.556m); Operating Margin: 12.6%; EBITDA: $194.365m; Net Income: $55.222m; EPS: $0.47; R&D: $53.27m; SG&A: $250.221m; Operating Expenses: $301.796m; Cash from Ops: $134.318m; Free Cash Flow: $115.45m; Cash at End of Period: $992.99m; Net Debt: $2.383b; Total Assets: $12.363b; Current Ratio: 3.33; Debt/Capitalization: 0.309; Debt/EBITDA: ~12.3x.
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Revenue |
720.28M |
5.30% |
8.35% |
| Gross Profit |
392.56M |
2.01% |
19.96% |
| Operating Income |
90.76M |
-11.54% |
3.17% |
| Net Income |
55.22M |
-41.23% |
33.27% |
| EPS |
0.47 |
-38.57% |
36.27% |
Key Financial Ratios
operatingProfitMargin
12.6%
operatingCashFlowPerShare
$1.14
freeCashFlowPerShare
$0.98
Management Commentary
No QQ2 2025 earnings call transcript data provided in the input. Consequently, no verbatim highlights or quotes from management can be cited in this report. If transcripts become available, they should be incorporated to enrich context on strategy, execution and near-term guidance.
Forward Guidance
Management did not publish formal quarterly guidance in the QQ2 2025 release. The company continues to allocate capital toward R&D and selective share repurchases, while maintaining a robust cash balance. Near-term drivers include ongoing demand for genomic workflows, assay platforms and life-science instrumentation, with potential upside from product portfolio expansion and adoption in pharma/biotech collaborations. Key watchpoints for the outlook include: (1) sustained demand in Diagnostics and Discovery segments, (2) competitive dynamics and pricing, (3) balance sheet leverage given net debt of approximately $2.38 billion and limited cushion in cash flow during periods of capex intensity or acquisitions, and (4) potential impairment considerations given substantial goodwill and intangible assets on the balance sheet.